171 related articles for article (PubMed ID: 29742643)
1. Pharmacokinetic Monitoring of Vancomycin in Cystic Fibrosis: Is It Time to Move Past Trough Concentrations?
Fusco NM; Prescott WA; Meaney CJ
Pediatr Infect Dis J; 2019 Mar; 38(3):258-262. PubMed ID: 29742643
[TBL] [Abstract][Full Text] [Related]
2. Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.
Fusco NM; Francisconi R; Meaney CJ; Duman D; Frederick CA; Prescott WA
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e103-e108. PubMed ID: 28903517
[TBL] [Abstract][Full Text] [Related]
3. An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus.
Stockmann C; Olson J; Rashid J; Lubsch L; Young DC; Hersh AL; Frymoyer A; Ampofo K; Liu X; Wang Y; Sherwin CMT; Zobell JT
J Clin Pharmacol; 2019 Feb; 59(2):198-205. PubMed ID: 30371946
[TBL] [Abstract][Full Text] [Related]
4. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
5. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
[TBL] [Abstract][Full Text] [Related]
6. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
7. The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant
Stoessel AM; Hale CM; Seabury RW; Miller CD; Steele JM
J Pharm Pract; 2019 Aug; 32(4):442-446. PubMed ID: 29554847
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
9. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
10. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
Beccari MV; Seabury RW; Mogle BT; Kufel WD; Miller CD; Steele JM
J Am Pharm Assoc (2003); 2020; 60(5):729-733. PubMed ID: 32224054
[TBL] [Abstract][Full Text] [Related]
11. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
Chen TT; Liu MP; Sun HC
Microbiol Spectr; 2022 Apr; 10(2):e0156221. PubMed ID: 35412391
[TBL] [Abstract][Full Text] [Related]
13. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
15. Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC?
Patel K; Crumby AS; Maples HD
Paediatr Drugs; 2015 Apr; 17(2):97-103. PubMed ID: 25644329
[TBL] [Abstract][Full Text] [Related]
16. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
17. First-Dose Vancomycin Pharmacokinetics Versus Empiric Dosing on Area-Under-the-Curve Target Attainment in Critically Ill Patients.
Flannery AH; Delozier NL; Effoe SA; Wallace KL; Cook AM; Burgess DS
Pharmacotherapy; 2020 Dec; 40(12):1210-1218. PubMed ID: 33176005
[TBL] [Abstract][Full Text] [Related]
18. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections.
Clark L; Skrupky LP; Servais R; Brummitt CF; Dilworth TJ
Ther Drug Monit; 2019 Aug; 41(4):483-488. PubMed ID: 30817704
[TBL] [Abstract][Full Text] [Related]
19. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
Prybylski JP
Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
